27371349|t|A Cyclin D2 -derived peptide acts on specific cell cycle phases by activating ERK1/2 to cause the death of breast cancer cells
27371349|a|Protein degradation by the proteasome generates functional intracellular peptides. Pep5, a peptide derived from Cyclin D2, induces cell death in tumor cell lines and reduces the volume of rat C6 glioblastoma tumors in vivo. Here, we chose the human MDA-MB-231 breast cancer cells to evaluate the mechanism of cell death induced by pep5 in different phases of the cell cycle. Fluorescently labeled pep5, monitored by real time confocal microscopy, entered the MDA-MB-231 cells 3min after application and localized to the nucleus and cytoplasm. Pep5 - induced cell death was increased when the MDA-MB-231 cell population was arrested at the G1/S transition or in S phase compared to asynchronous cells. Pep5 induced permanent extracellular signal-regulated kinase (ERK1/2) phosphorylation in MDA-MB-231 cells synchronized in G1/S or S phase. Affinity chromatography followed by mass spectrometry identified CLIC1 and Plectin as the only two proteins that interacted with pep5 in both asynchronous and synchronized MDA-MB-231 cells. These interactions could explain the long-lasting ERK1/2 phosphorylation and the cytoskeleton perturbations in the MDA-MB-231 cells, in which the stress fibers ' integrity is affected by pep5 treatments. These data suggest that pep5 has potential therapeutic properties for treating specific types of cancers, such as breast cancer cells. Pep5, a natural intracellular peptide formed by the degradation of Cyclin D2 through the ubiquitin-proteasome system, induces cell death when reintroduced into MDA-MB-231 breast cancer cells, which express low levels of Cyclin D2, specifically in G1/S arrested cells or in cells that are passing through S phase. Under these conditions, pep5 is able to interact with different intracellular proteins, primarily cytoskeleton and proteasome components, which can lead to cellular apoptosis. Together, our data suggest that pep5 is an intracellular peptide with therapeutic potential for treating specific types of tumors with low expression of Cyclin D2 by inhibiting cell proliferation.
27371349	2	11	Cyclin D2	T116,T123	C2718191
27371349	21	28	peptide	T116	C0030956
27371349	37	45	specific	T080	C0205369
27371349	46	63	cell cycle phases	T043	C1516337
27371349	67	77	activating	T052	C1879547
27371349	78	84	ERK1/2	T116,T126	C0600388
27371349	88	103	cause the death	T033	C0007465
27371349	107	126	breast cancer cells	T025	C1512505
27371349	127	146	Protein degradation	T044	C0597304
27371349	154	164	proteasome	T044	C1752727
27371349	175	185	functional	T169	C0205245
27371349	186	199	intracellular	T082	C0178719
27371349	200	208	peptides	T116	C0030956
27371349	210	214	Pep5	T116	C0030956
27371349	218	225	peptide	T116	C0030956
27371349	239	248	Cyclin D2	T116,T123	C2718191
27371349	250	257	induces	T169	C0205263
27371349	258	268	cell death	T043	C0007587
27371349	272	288	tumor cell lines	T025	C0085983
27371349	293	300	reduces	T080	C0392756
27371349	305	311	volume	T081	C0449468
27371349	315	318	rat	T015	C0034693
27371349	319	341	C6 glioblastoma tumors	T191	C0017636
27371349	342	349	in vivo	T082	C1515655
27371349	370	386	human MDA-MB-231	T050	C3898556
27371349	387	406	breast cancer cells	T025	C1512505
27371349	410	418	evaluate	T058	C0220825
27371349	423	446	mechanism of cell death	T043	C1708951
27371349	447	454	induced	T169	C0205263
27371349	458	462	pep5	T116	C0030956
27371349	466	475	different	T080	C1705242
27371349	476	500	phases of the cell cycle	T043	C1516337
27371349	502	523	Fluorescently labeled	T059	C0079367
27371349	524	528	pep5	T116	C0030956
27371349	543	572	real time confocal microscopy	T059	C0242842
27371349	586	596	MDA-MB-231	T050	C3898556
27371349	597	602	cells	T025	C1512505
27371349	630	639	localized	T082	C0392752
27371349	647	654	nucleus	T026	C0007610
27371349	659	668	cytoplasm	T026	C0010834
27371349	670	674	Pep5	T116	C0030956
27371349	677	684	induced	T169	C0205263
27371349	685	695	cell death	T043	C0007587
27371349	700	709	increased	T081	C0205217
27371349	719	729	MDA-MB-231	T050	C3898556
27371349	730	745	cell population	T025	C1512505
27371349	750	758	arrested	T079	C0237477
27371349	766	781	G1/S transition	T044	C1517341
27371349	788	795	S phase	T079	C0080129
27371349	796	804	compared	T052	C1707455
27371349	808	820	asynchronous	T079	C0439581
27371349	821	826	cells	T025	C0007634
27371349	828	832	Pep5	T116	C0030956
27371349	833	840	induced	T169	C0205263
27371349	841	850	permanent	T079	C0205355
27371349	851	888	extracellular signal-regulated kinase	T116,T126	C0600388
27371349	890	896	ERK1/2	T116,T126	C0600388
27371349	898	913	phosphorylation	T044	C0031715
27371349	917	927	MDA-MB-231	T050	C3898556
27371349	928	933	cells	T025	C1512505
27371349	934	946	synchronized	T079	C0439580
27371349	950	954	G1/S	T044	C1517341
27371349	958	965	S phase	T079	C0080129
27371349	967	990	Affinity chromatography	T059	C0008551
27371349	1003	1020	mass spectrometry	T059	C0037813
27371349	1021	1031	identified	T080	C0205396
27371349	1032	1037	CLIC1	T116,T123	C1314856
27371349	1042	1049	Plectin	T116,T123	C0071277
27371349	1066	1074	proteins	T116,T123	C0033684
27371349	1080	1090	interacted	T169	C1704675
27371349	1096	1100	pep5	T116	C0030956
27371349	1109	1121	asynchronous	T079	C0439581
27371349	1126	1138	synchronized	T079	C0439580
27371349	1139	1149	MDA-MB-231	T050	C3898556
27371349	1150	1155	cells	T025	C1512505
27371349	1163	1175	interactions	T169	C1704675
27371349	1207	1213	ERK1/2	T116,T126	C0600388
27371349	1214	1229	phosphorylation	T044	C0031715
27371349	1238	1250	cytoskeleton	T026	C0010853
27371349	1251	1264	perturbations	T169	C0332453
27371349	1272	1282	MDA-MB-231	T050	C3898556
27371349	1283	1288	cells	T025	C1512505
27371349	1303	1316	stress fibers	T026	C0887904
27371349	1319	1328	integrity	T080	C1947912
27371349	1344	1348	pep5	T116	C0030956
27371349	1349	1359	treatments	T061	C0087111
27371349	1367	1371	data	T078	C1511726
27371349	1385	1389	pep5	T116	C0030956
27371349	1394	1403	potential	T080	C3245505
27371349	1404	1415	therapeutic	T169	C0302350
27371349	1416	1426	properties	T080	C0871161
27371349	1431	1439	treating	T061	C0087111
27371349	1440	1454	specific types	T080	C0332307
27371349	1458	1465	cancers	T191	C0006826
27371349	1475	1494	breast cancer cells	T025	C1512505
27371349	1496	1500	Pep5	T116	C0030956
27371349	1512	1525	intracellular	T082	C0178719
27371349	1526	1533	peptide	T116	C0030956
27371349	1548	1572	degradation of Cyclin D2	T044	C0597304
27371349	1585	1612	ubiquitin-proteasome system	T044	C1523807
27371349	1614	1621	induces	T169	C0205263
27371349	1622	1632	cell death	T043	C0007587
27371349	1656	1666	MDA-MB-231	T050	C3898556
27371349	1667	1686	breast cancer cells	T025	C1512505
27371349	1702	1712	low levels	T080	C0441889
27371349	1716	1725	Cyclin D2	T116,T123	C2718191
27371349	1743	1747	G1/S	T044	C1517341
27371349	1748	1762	arrested cells	T025	C0007634
27371349	1769	1774	cells	T025	C0007634
27371349	1800	1807	S phase	T079	C0080129
27371349	1833	1837	pep5	T116	C0030956
27371349	1849	1857	interact	T169	C1704675
27371349	1873	1886	intracellular	T082	C0178719
27371349	1887	1895	proteins	T116,T123	C0033684
27371349	1907	1919	cytoskeleton	T026	C0010853
27371349	1924	1945	proteasome components	T116,T126	C0208355
27371349	1957	1961	lead	T169	C1522538
27371349	1965	1983	cellular apoptosis	T043	C0162638
27371349	1999	2003	data	T078	C1511726
27371349	2017	2021	pep5	T116	C0030956
27371349	2028	2041	intracellular	T082	C0178719
27371349	2042	2049	peptide	T116	C0030956
27371349	2055	2066	therapeutic	T169	C0302350
27371349	2067	2076	potential	T080	C3245505
27371349	2081	2089	treating	T061	C0087111
27371349	2090	2104	specific types	T080	C0332307
27371349	2108	2114	tumors	T191	C0027651
27371349	2120	2123	low	T080	C0205251
27371349	2124	2134	expression	T045	C1171362
27371349	2138	2147	Cyclin D2	T116,T123	C2718191
27371349	2151	2161	inhibiting	T052	C3463820
27371349	2162	2180	cell proliferation	T043	C0596290